TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29101463
Drug: Dovitinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib (300 mg in 5 days on/2 days off schedule) with fluvoxamine
Study: 29101463
Drug: Dovitinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib (300 mg in 5 days on/2 days off schedule) without fluvoxamine
Study: 29103916
Drug: Atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin + Torcetrapib
Study: 29103916
Drug: Atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin + Placebo
Study: 29107441
Drug: Hydroxyurea, median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea, median treatment duration 7 years, mean therapeutic dose 18±4.7 mg/kg/day
Study: 29107621
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin (30 mg/kg)
Study: 29109077
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of mRNA-transfected c-Met-CAR T cells (3 × 10^6 cells)
Study: 29110152
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus trastuzumab (plus endocrine therapy for ER-positive tumors)
Study: 29110849
Drug: Afatinib monotherapy
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib monotherapy (40mg daily)
Study: 29110849
Drug: Afatinib plus
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib plus cetuximab (afatinib 40mg daily + cetuximab 500mg/m)
Study: 29110849
Drug: Afatinib plus
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib plus cetuximab for patients who received afatinib monotherapy for ≥12 weeks
Study: 29110849
Drug: Afatinib plus
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib plus cetuximab for patients who received afatinib monotherapy for <12 weeks
Study: 29111011
Drug: Natalizumab therapy
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab therapy
Study: 29112634
Drug: Therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with sympathomimetic drugs and fluid therapy
Study: 29112650
Drug: 1,500-mL intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500-mL intravenous fluid bolus
Study: 29112650
Drug: 500-mL intravenous
Normalized name: lifileucel
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mL intravenous fluid bolus
Study: 29115994
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of omeprazole, midazolam, dextromethorphan, and fexofenadine administered to assess drug metabolizing enzymes activity.
Study: 29119917
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli PNP delivered via recombinant adenoviral vector followed by systemic administration of fludarabine phosphate
Study: 29121278
Drug: Ketamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine and less volatile anaesthetic co-administration
Study: 29121645
Drug: Dasatinib treatment
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib treatment for a median of nine months
Study: 29121645
Drug: Dasatinib treatment
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib treatment
Study: 29121934
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg/day for 12 weeks
Study: 29123425
Drug: tolvaptan (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolvaptan (60-120 mg/d)
Study: 29124456
Drug: Exemestane with
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane with low-dose oral cyclophosphamide
Study: 29124506
Drug: Albuterol after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol after biofeedback sessions
Study: 29124506
Drug: Budesonide (high-potency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (high-potency inhaled steroid)
Study: 29124992
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.15-mg/kg bolus with continuous infusion at 2 µg/kg/min)
Study: 29126426
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implants in the maxilla (six implants each, loaded within 24 hours, definitive restoration after 20-24 weeks)
Study: 29126426
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implants in the maxilla
Study: 29126871
Drug: Lumacaftor/ivacaftor (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor/ivacaftor (full dose)
Study: 29126871
Drug: Lumacaftor/ivacaftor (half
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor/ivacaftor (half dose)
Study: 29126871
Drug: Lumacaftor/ivacaftor (half
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor/ivacaftor (half dose increased to full dose)
Study: 29127195
Drug: Microcatheter contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcatheter contrast injection (MCI) prior to stent retriever deployment
Study: 29128389
Drug: Initial antibiotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotic therapy (IAT); mean duration 7.8 days; most patients received monotherapy (72.5%)
Study: 30774399
Drug: Initial antibiotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotic therapy (IAT)
Study: 29128828
Drug: Diprospan (betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprospan (betamethasone dual-acting formulation) administered via single-dose intramuscular injection
Study: 29129018
Drug: BIAsp 30
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BIAsp 30 once daily (OD), with the possibility of stepwise treatment intensification up to BIAsp 30 three times daily (TID)
Study: 29129018
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine OD, with the possibility of stepwise treatment intensification with insulin aspart up to TID
Study: 29132341
Drug: Sinovial H-L®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinovial H-L® (hybrid formulation of hyaluronic acid)
Study: 29133316
Drug: NKR-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NKR-2 treatment administered three times with a 2-week interval between each administration.
Study: 29133513
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) 10 mg/kg IV every 2 weeks combined with Vorinostat (VOR) 400 mg p.o. daily for 7 days on, 7 days off, in a 28-day cycle
Study: 29134606
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (500 or 1000 mg) as intravenous infusions
Study: 29134606
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (500 or 1000 mg)
Study: 29134664
Drug: Ruxolitinib BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib BID (doses based on platelets count), continuously in 28-day cycles for the first 3 cycles
Study: 29134664
Drug: Azacytidine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacytidine 25 mg/m2
Study: 29135575
Drug: Standard antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiretroviral therapy
Study: 29136201
Drug: Selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75 mg monotherapy
Study: 29136201
Drug: Selumetinib 25
Normalized name: selumetinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib 25 mg plus docetaxel 60 mg/m2
Study: 29136201
Drug: Selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75 mg plus docetaxel 60 mg/m2
Study: 29136201
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (selumetinib plus docetaxel)
Study: 29136201
Drug: Selumetinib 50
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 50 mg monotherapy
Study: 29136317
Drug: Belatacept/sirolimus immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belatacept/sirolimus immunotherapy
Study: 29137560
Drug: Abstinence-contingent monetary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence-contingent monetary incentives added to cessation treatments (PV only, PV+Q, PV+CBT) for four weeks after a quit attempt.
Study: 29137560
Drug: Prescriber visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriber visit for pharmacotherapy only (PV only).
Study: 29137560
Drug: Prescriber visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriber visit and telephone cognitive-behavioral therapy (PV+CBT).
Study: 29138320
Drug: RTS,S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S vaccine (recombinant circumsporozoite protein-based vaccine)
Study: 29138340
Drug: Chimeric Antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric Antigen Receptor-Modified T Cells
Study: 29138569
Drug: Fluvoxamine (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50-300 mg/day for 90 days)
Study: 29138986
Drug: Secukinumab 10
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks (starting from week 8)
Study: 29138986
Drug: Secukinumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (both dose groups)
Study: 29139135
Drug: Quizartinib 60
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib 60 mg/d for 7 days (DL1; n=6)
Study: 29139135
Drug: Quizartinib 60
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib 60 mg/d for 14 days (DL2; n=7)
Study: 29139135
Drug: Quizartinib 40
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib 40 mg/d for 14 days (DL-1; n=6)
Study: 29139135
Drug: Quizartinib in
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib in combination with SOC chemotherapy
Study: 29140548
Drug: SANGUINATE (SG)
Normalized name: sanguinarine
DrugBank: Pegylated carboxyhemoglobin (bovine) (DB17720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SANGUINATE (SG) infusion, 320 mg/kg, three weekly infusions
Study: 29140548
Drug: SANGUINATE (SG)
Normalized name: sanguinarine
DrugBank: Pegylated carboxyhemoglobin (bovine) (DB17720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SANGUINATE (SG) infusion
Study: 29140978
Drug: 8-item Morisky
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-item Morisky Medication Adherence Scale (MMAS-8)
Study: 29141662
Drug: Combined autologous
Normalized name: chondrocytes, autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined autologous adipose-derived mesenchymal stem cells (AT-MSCs) and hyaluronic acid (HA) derivative, single intradiscal injection at a dose of 2 × 10.
Study: 29142066
Drug: SGN-CD123A, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGN-CD123A, an antibody-drug conjugate targeting CD123
Study: 29142375
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg for 7 days)
Study: 29142987
Drug: Heparin-avoidance hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-avoidance hemodialysis protocol using airless dialysis tubing
Study: 29142987
Drug: Heparin-avoidance hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-avoidance hemodialysis protocol
Study: 29143287
Drug: Lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoic acid (LA) 1200 mg oral administration
Study: 29143919
Drug: iGlarLixi (fixed-ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlarLixi (fixed-ratio combination of insulin glargine U100 + lixisenatide)
Study: 29143919
Drug: iGlar (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlar (insulin glargine U100)
Study: 29144985
Drug: Rigosertib (650-1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigosertib (650-1700 mg/m2) administered via continuous intravenous infusion for 3-7 days
Study: 29145039
Drug: SAR125844 (MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR125844 (MET kinase inhibitor) at a maximum tolerated dose (MTD) of 570 mg/m
Study: 29145895
Drug: hs-cTnT ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT ≥ 0.02 µg/l
Study: 29145895
Drug: hs-cTnI ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnI ≥ 5.5 ng/l
Study: 29146409
Drug: Lurasidone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone monotherapy (20 to 120 mg/day)
Study: 29146409
Drug: Lurasidone adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone adjunctive therapy with lithium or valproate (20 to 120 mg/day)
Study: 29147617
Drug: hu3F8 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu3F8 monoclonal antibody
Study: 29149283
Drug: RotaTeq vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RotaTeq vaccine after first dose
Study: 29149283
Drug: RotaTeq vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RotaTeq vaccine after second dose
Study: 29149283
Drug: RotaTeq vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RotaTeq vaccine after third dose
Study: 29149914
Drug: Motivational interviewing-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing-based brief intervention (MIBI) as an adjunct to usual care
Study: 29150536
Drug: Cessation medications
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cessation medications
Study: 29150844
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied GSK2981278 ointment
Study: 29153636
Drug: Intensified medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified medical therapy for elevated LDH
Study: 29153775
Drug: Weekly Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly Paclitaxel (90 mg/m²), Carboplatin, and Bevacizumab
Study: 29153823
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg every 2 weeks, with dose increase to 150 mg every 2 weeks at week 12 if LDL-C ≥70 mg/dL at week 8)
Study: 29153856
Drug: Viscous soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscous soluble fiber supplementation (median dose of 8.7 g/day, range 1.45-30 g/day)
Study: 29153976
Drug: Pharmacoscopy-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacoscopy-guided treatment
Study: 29155313
Drug: Deferasirox at
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox at an initial dose of 10 mg/kg/day, with up-titration to a maximum of 20 mg/kg/day for 52 weeks.
Study: 29155313
Drug: Deferasirox treatment
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox treatment
Study: 29155991
Drug: PAS-LAR 60
Normalized name: pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAS-LAR 60 mg monotherapy
Study: 29155991
Drug: PAS-LAR 60
Normalized name: pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAS-LAR 60 mg with 50% reduced pegvisomant dose
Study: 29155991
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PAS-LAR and pegvisomant
Study: 29156708
Drug: Refametinib in
Normalized name: Refametinib
DrugBank: Refametinib (DB06309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refametinib in combination with copanlisib
Study: 29156708
Drug: Refametinib in
Normalized name: Refametinib
DrugBank: Refametinib (DB06309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refametinib in combination with lapatinib
Study: 29156802
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus carboplatin followed by pemetrexed maintenance therapy
Study: 29157306
Drug: 9-peptide breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-peptide breast cancer vaccine plus poly-ICLC
Study: 29158179
Drug: Definite hemostatic
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definite hemostatic treatment (alone or in combination with surgery, chemotherapy, radiotherapy, or radiologic embolization)
Study: 29158365
Drug: Capecitabine 850
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 850 mg/m², Oxaliplatin, Celecoxib with concurrent radiation therapy
Study: 29158367
Drug: Necuparanib 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necuparanib 0.5 mg/kg + gemcitabine
Study: 29158367
Drug: Necuparanib 1
Normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necuparanib 1 mg/kg + gemcitabine
Study: 29158367
Drug: Necuparanib 2
Normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necuparanib 2 mg/kg + nab-paclitaxel + gemcitabine
Study: 29158367
Drug: Necuparanib 4
Normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necuparanib 4 mg/kg + nab-paclitaxel + gemcitabine
Study: 29158367
Drug: Necuparanib 5
Normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necuparanib 5 mg/kg + nab-paclitaxel + gemcitabine
Study: 29158367
Drug: Necuparanib 6
Normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necuparanib 6 mg/kg + nab-paclitaxel + gemcitabine
Study: 29158421
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy in urban hospitals (2001: 54%, 2011: not specified)
Study: 29158421
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy in rural hospitals (2001: 57%, 2011: not specified)
Study: 29158913
Drug: Video-based family-oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-based family-oriented treatment for peripartum depression
Study: 29159083
Drug: Canagliflozin 50
Normalized name: canagliflozin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 50 mg BID
Study: 29159083
Drug: Canagliflozin 150
Normalized name: canagliflozin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 150 mg BID
Study: 29159458
Drug: Elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elosulfase alfa 4.0 mg/kg/week
Study: 29159458
Drug: Combined dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dosage groups (2.0 mg/kg/week and 4.0 mg/kg/week)
Study: 29159476
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) administered as part of the FOLFOX regimen
Study: 29159476
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) dosage per kg lean body mass (LBM)
Study: 29159476
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) dosage for hematological toxicities
Study: 29160301
Drug: Citalopram/Escitalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram/Escitalopram treatment
Study: 29162063
Drug: Not on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not on anti-retroviral therapy at baseline
Study: 29162134
Drug: Anastrozole monotherapy
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole monotherapy
Study: 29162718
Drug: Fluticasone hydrofluoroalkane
Normalized name: HYDROFLUOROALKANE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone hydrofluoroalkane inhaled via pMDI with no delay between shaking and actuation
Study: 29164334
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (1 µg/kg) test before extubation
Study: 29166901
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen prescription
Study: 29167744
Drug: Daily parental
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily parental ATS reports
Study: 29169399
Drug: PReDicT Test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PReDicT Test guided treatment
Study: 29170088
Drug: Mifepristone (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200mg orally) and misoprostol (400 mcg sublingually in Moldova; 800 mcg buccally at all other sites)
Study: 29171941
Drug: Extracorporeal cellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal cellular therapy (ELAD) plus standard of care (SOC) for 3-5 days
Study: 29174484
Drug: Glucocorticoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid treatment for 1 year or longer
Study: 29174484
Drug: No glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No glucocorticoid treatment or cumulative treatment duration of less than 1 month
Study: 29174546
Drug: Ledipasvir and
Normalized name: Ledipasvir and Sofosbuvir Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir and Sofosbuvir (90 mg ledipasvir + 400 mg sofosbuvir, once daily for 12 weeks)